Relmada Therapeutics, Inc.
RLMD
$6.27
$0.559.62%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 37.33M | 32.22M | 28.04M | 33.60M | 34.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.44M | 56.20M | 57.84M | 70.52M | 79.12M |
| Operating Income | -57.44M | -56.20M | -57.84M | -70.52M | -79.12M |
| Income Before Tax | -58.88M | -57.39M | -56.17M | -67.81M | -75.71M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.88 | -57.39 | -56.17 | -67.81 | -75.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.88M | -57.39M | -56.17M | -67.81M | -75.71M |
| EBIT | -57.44M | -56.20M | -57.84M | -70.52M | -79.12M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.15 | -1.50 | -1.80 | -2.21 | -2.50 |
| Normalized Basic EPS | -0.68 | -0.92 | -1.12 | -1.39 | -1.58 |
| EPS Diluted | -1.15 | -1.50 | -1.80 | -2.21 | -2.50 |
| Normalized Diluted EPS | -0.68 | -0.92 | -1.12 | -1.39 | -1.58 |
| Average Basic Shares Outstanding | 214.08M | 157.89M | 126.97M | 123.95M | 120.93M |
| Average Diluted Shares Outstanding | 214.08M | 157.89M | 126.97M | 123.95M | 120.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |